Stocktoria
Verastem, Inc. VSTM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2011-11-08
Verastem, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $30.9M | $10.0M | — | $2.6M | $2.1M |
| R&D expense | $114.6M | $81.3M | $61.4M | $50.6M | $39.3M |
| SG&A expense | $81.1M | $43.6M | $30.7M | $25.0M | $24.1M |
| Operating income | -$170.1M | -$115.0M | -$92.1M | -$72.9M | -$61.4M |
| Interest expense | $1.1M | $4.6M | $4.1M | $2.1M | $10.0M |
| Income tax | — | $185,000 | — | $0 | $0 |
| Net income | -$209.5M | -$130.6M | -$87.4M | -$73.8M | -$71.2M |
| EPS (diluted) | $-3.02 | $-3.66 | $-3.96 | $-4.57 | $-4.90 |
| Operating cash flow | -$137.5M | -$104.8M | -$86.5M | -$63.7M | -$53.5M |
| Free cash flow | — | -$104.8M | — | — | -$53.7M |
| Cash & equivalents | $205.0M | $88.8M | $77.9M | $74.9M | $21.3M |
| Inventory | $1.8M | — | — | — | — |
| Total assets | $246.4M | $101.5M | $149.7M | $95.0M | $108.7M |
| Total liabilities | $189.2M | $130.4M | $71.2M | $47.7M | $21.1M |
| Shareholders' equity | $57.2M | -$28.9M | $57.4M | $47.4M | $87.6M |
Source: SEC EDGAR filings · CIK 0001526119 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.